Has ERIS Lifescience declared dividend?

ERIS Lifesciences Ltd has declared a 735% dividend, amounting to ₹7.35 per share, with an ex-date of February 13, 2025. The company has shown strong price returns over various periods, indicating robust performance and potential shareholder value.

ERIS Lifesciences Ltd has declared a 735% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 735%<BR>- Amount per share: 7.35<BR>- Ex-date: 13 Feb 25<BR><BR>Dividend Yield: 0.45%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 11.46%, the dividend return was 0.49%, resulting in a total return of 11.95%.<BR><BR>Over the past year, the price return reached 67.08%, with a dividend return of 0.73%, leading to a total return of 67.81%.<BR><BR>For the two-year period, the price return was 154.22%, the dividend return was 1.09%, culminating in a total return of 155.31%.<BR><BR>In the three-year span, the price return stood at 146.99%, the dividend return was 2.31%, resulting in a total return of 149.3%.<BR><BR>Over the last four years, the price return was 127.14%, with a dividend return of 2.95%, giving a total return of 130.09%.<BR><BR>Finally, in the five-year period, the price return was 223.91%, the dividend return was 5.85%, leading to a total return of 229.76%.<BR><BR>Overall, ERIS Lifesciences has declared a significant dividend, which, combined with strong price returns over multiple periods, indicates a robust performance and potential for shareholder value.

Who are the peers of the ERIS Lifescience?

ERIS Lifescience's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca, Alembic Pharma, Concord Biotech, Jubilant Pharma, and Caplin Point Lab. ERIS Lifescience has a 1-year return of 75.46%, outperforming its peers, with Divi's Lab leading at 51.96% and Cipla at 0.86%.

Peers: The peers of ERIS Lifescience are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, Alembic Pharma, Concord Biotech, Jubilant Pharmo, and Caplin Point Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, ERIS Lifescience, Alembic Pharma, and Caplin Point Lab, and Average management risk is noted at Jubilant Pharmo. Growth ratings show Excellent growth at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, ERIS Lifescience, Alembic Pharma, and the rest. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Astrazeneca Phar, ERIS Lifescience, Alembic Pharma, and Caplin Point Lab, while Good capital structure is found at Torrent Pharma, and Average capital structure is seen at Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Cipla at 0.86%. ERIS Lifescience's 1-year return of 75.46% is significantly higher than both. Additionally, Alembic Pharma and Jubilant Pharmo have negative six-month returns.

Who are in the management team of ERIS Lifescience?

As of March 2022, the management team of ERIS Lifescience includes Amit Indubhushan Bakshi (CMD & Executive Director), Kaushal Kamlesh Shah, Inderjeet Singh Negi, Krishnakumar Vaidyanathan (Executive Director/WTD/Chairman), and four Independent Non-Executive Directors: Sujesh Vasudevan, Prashant Gupta, Rajeev Narotam Dalal, and Kalpana Unadkat. They oversee the company's strategic direction and governance.

As of March 2022, the management team of ERIS Lifescience includes the following individuals:<BR><BR>1. Amit Indubhushan Bakshi - CMD & Executive Director<BR>2. Kaushal Kamlesh Shah - WTD & Executive Director<BR>3. Inderjeet Singh Negi - WTD & Executive Director<BR>4. Krishnakumar Vaidyanathan - Executive Director / WTD / Chairman<BR>5. Sujesh Vasudevan - Independent Non-Executive Director<BR>6. Prashant Gupta - Independent Non-Executive Director<BR>7. Rajeev Narotam Dalal - Independent Non-Executive Director<BR>8. Kalpana Unadkat - Independent Non-Executive Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

What does ERIS Lifescience do?

Eris Lifesciences Ltd manufactures and markets pharmaceutical products and is classified as a Large Cap company. As of March 2025, it reported net sales of ₹7,053 Cr and a net profit of ₹938 Cr.

Overview: <BR>Eris Lifesciences Ltd is engaged in the manufacturing and marketing of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and is categorized as a Large Cap company.<BR><BR>History: <BR>Eris Lifesciences Limited was incorporated on January 25, 2007, and changed its name to 'Eris Lifesciences Private Limited' on February 9, 2007. The company was converted into a Public Limited Company and rebranded as 'Eris Lifesciences Limited' on February 2, 2017. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 7,053 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 938 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 24,168 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 68.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.42% <BR>Debt-Equity: 0.79 <BR>Return on Equity: 12.35% <BR>Price to Book: 8.31 <BR><BR>Contact Details: <BR>Address: 8th Floor Commerce House -IV, Prahladnagar 100 FT Road Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-30451000 <BR>Email: complianceofficer@erislifesciences. <BR>Website: http://www.eris.co.in

Who are the top shareholders of the ERIS Lifescience?

The top shareholders of ERIS Lifescience include promoter Amit Indubhusan Bakshi with 42.84%, mutual funds holding 16.59%, foreign institutional investors at 8.43%, and the highest public shareholder, Lilac Investments Limited, with 8.79%. Individual investors collectively own 9.16% of the shares.

The top shareholders of ERIS Lifescience include the promoters, who hold a significant majority of the shares. The promoter with the highest holding is Amit Indubhusan Bakshi, owning 42.84% of the company. Additionally, mutual funds hold 16.59% of the shares, represented by 22 schemes, while foreign institutional investors (FIIs) account for 8.43% through 135 different entities. The highest public shareholder is Lilac Investments Limited, which holds 8.79%. Individual investors collectively own 9.16% of the shares.

How big is ERIS Lifescience?

As of 24th July, ERIS Lifesciences Ltd has a market capitalization of 24,385.00 Cr, with recent Net Sales of 2,893.64 Cr and a Net Profit of 352.37 Cr. The company reports Shareholder's Funds of 2,854.36 Cr and Total Assets of 6,744.13 Cr.

As of 24th July, ERIS Lifesciences Ltd has a market capitalization of 24,385.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 2,893.64 Cr and a Net Profit of 352.37 Cr.<BR><BR>The latest annual period shows Shareholder's Funds of 2,854.36 Cr and Total Assets amounting to 6,744.13 Cr.

Are ERIS Lifescience latest results good or bad?

ERIS Lifesciences reported strong financial results for Q2 2025, with a profit after tax of Rs 117.99 crore, a 41.6% year-on-year growth, and net sales of Rs 773.00 crore, up 7.40%. While sales growth has slowed compared to last year, the company shows improved profitability and operational efficiency.

ERIS Lifesciences has reported strong financial results for the quarter ending June 2025, indicating a positive performance overall. The company achieved a profit after tax (PAT) of Rs 117.99 crore, which reflects a significant year-on-year growth of 41.6%. This is a notable improvement compared to the previous year when the PAT was negative.<BR><BR>Net sales reached Rs 773.00 crore, marking a 7.40% increase from the previous year, although this growth rate is lower than the 54.24% seen in the same quarter last year. However, the operating profit (PBDIT) also saw a healthy increase, reaching Rs 276.71 crore with an operating profit margin of 35.80%, demonstrating improved efficiency.<BR><BR>Overall, the financial metrics suggest that ERIS Lifesciences is performing well, particularly in terms of profitability and operational efficiency, despite a slight slowdown in sales growth compared to the previous year.

Is ERIS Lifescience overvalued or undervalued?

As of September 5, 2025, ERIS Lifescience is considered overvalued with a valuation grade of "expensive," reflected in its high PE ratio of 60.82 and EV to EBITDA ratio of 24.71, especially when compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 26.09% that underperformed against the Sensex's 3.29%.

As of 5 September 2025, the valuation grade for ERIS Lifescience has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 60.82, an EV to EBITDA ratio of 24.71, and a PEG ratio of 37.14, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Sun Pharma has a PE ratio of 33.33 and an EV to EBITDA of 22.53, while Cipla is more attractively valued with a PE of 23.25 and an EV to EBITDA of 16.37. The high valuation metrics of ERIS Lifescience suggest that it is trading at a premium compared to its peers, which reinforces the conclusion of being overvalued. Notably, despite recent stock performance showing a 26.09% return year-to-date, it has underperformed against the Sensex's 3.29% return during the same period.

When is the next results date for ERIS Lifescience?

The next results date for ERIS Lifescience is 12 November 2025.

The next results date for ERIS Lifescience is scheduled for 12 November 2025.

How has been the historical performance of ERIS Lifescience?

ERIS Lifescience has shown significant growth, with net sales increasing from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025, and operating profit rising from 376.60 Cr to 1,035.56 Cr. However, profit after tax fluctuated, peaking at 406.11 Cr in March 2022 and declining to 351.84 Cr by March 2025.

Answer:<BR>The historical performance of ERIS Lifescience shows significant growth in net sales and operating profit over the years, with net sales reaching 2,893.64 Cr in March 2025, up from 1,074.06 Cr in March 2020. The operating profit (PBDIT) also increased to 1,035.56 Cr in March 2025 from 376.60 Cr in March 2019. However, profit after tax saw fluctuations, peaking at 406.11 Cr in March 2022 before declining to 351.84 Cr in March 2025. The company's total assets grew from 1,381.39 Cr in March 2020 to 6,744.13 Cr in March 2025, while total liabilities increased from 1,381.39 Cr to 6,744.13 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,065.00 Cr in March 2025 compared to 271.00 Cr in March 2020.<BR><BR>Breakdown:<BR>ERIS Lifescience has demonstrated a robust upward trend in its financial performance, particularly in net sales, which surged from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025. This growth in revenue is accompanied by a notable increase in operating profit, which rose from 376.60 Cr to 1,035.56 Cr over the same period. Despite this positive trend, profit after tax experienced some volatility, peaking at 406.11 Cr in March 2022 before settling at 351.84 Cr in March 2025. The company's total assets expanded significantly, reflecting its growth strategy, climbing from 1,381.39 Cr to 6,744.13 Cr. Total liabilities mirrored this growth, also increasing to 6,744.13 Cr. Cash flow from operating activities saw a remarkable improvement, indicating enhanced operational efficiency, with figures rising from 271.00 Cr in March 2020 to 1,065.00 Cr in March 2025.

Should I buy, sell or hold ERIS Lifescience?

Is ERIS Lifescience technically bullish or bearish?

As of December 1, 2025, ERIS Lifescience's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bearish MACD and KST indicators, while moving averages suggest a slight bullish stance on the daily chart.

As of 1 December 2025, the technical trend for ERIS Lifescience has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bearish on both weekly and monthly time frames, while the Bollinger Bands show a bearish signal weekly but mildly bullish monthly. The moving averages indicate a mildly bullish stance on the daily chart, contrasting with the bearish signals from the KST on both weekly and monthly time frames. The Dow Theory suggests a mildly bullish trend on the weekly chart, but there is no clear trend on the monthly. Overall, the lack of strong bullish or bearish signals and the sideways trend indicate a neutral stance with no clear strength in either direction.

Which are the latest news on ERIS Lifescience?

Why is ERIS Lifescience falling/rising?

As of 04-Dec, ERIS Lifesciences Ltd's stock price is rising to 1,564.00 after a trend reversal, despite recent declines. The company shows strong year-to-date performance and management efficiency, but is currently trading below moving averages and experiencing reduced investor participation.

As of 04-Dec, ERIS Lifesciences Ltd's stock price is rising, currently at 1,564.00, with a change of 2.15 (0.14%) upward. This increase follows a trend reversal after seven consecutive days of decline, indicating a potential shift in market sentiment. Despite the recent downturn, the stock has shown strong performance over the year-to-date, with a return of 14.25%, significantly outperforming the Sensex, which has returned 9.12% in the same period.<BR><BR>The company has demonstrated high management efficiency, reflected in a return on capital employed (ROCE) of 16.70%, and a low debt to EBITDA ratio of 1.32 times, showcasing its strong ability to service debt. Furthermore, ERIS Lifesciences has reported positive results for the last three consecutive quarters, with notable figures such as an operating cash flow of Rs 1,065.01 Cr and net sales of Rs 792.41 Cr, which contribute to investor confidence.<BR><BR>However, it is important to note that the stock is currently trading below its moving averages across various time frames, indicating a bearish trend in the short term. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 66.18% compared to the five-day average. Despite these challenges, the stock's consistent returns over the past three years and high institutional holdings at 26.57% suggest that there is still a solid foundation for its performance, contributing to the recent rise in its stock price.